Rune V. Overgaard
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies.
Journal: Diabetes, obesity & metabolism
Published: March 18, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
Journal: Diabetes, obesity & metabolism
Published: January 15, 2026
Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.
Journal: Diabetes, obesity & metabolism
Published: December 22, 2025
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.
Journal: Diabetes, obesity & metabolism
Published: March 30, 2023
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.
Journal: Cell reports. Medicine
Published: April 20, 2021
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.
Journal: Clinical pharmacokinetics
Published: April 12, 2021
Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Journal: The Journal of clinical endocrinology and metabolism
Published: July 29, 2020
Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.
Journal: Diabetes, obesity & metabolism
Published: December 09, 2019
Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.
Journal: The AAPS journal
Published: April 17, 2019
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: February 04, 2019
Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Journal: Diabetes, obesity & metabolism
Published: May 18, 2018
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 15, 2018
Last Updated: 09/26/2026